Discovering new drugs to treat neurodegenerative and neuropsychiatric pathologies is a major challenge since these disorders are extremely disabling for the patient and have a direct impact on families and loved ones.
We have chosen to concentrate our research activities on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease which are characterized by the abnormal accumulation of certain proteins. Our clinical portfolio currently includes drug candidates in post-stroke functional recovery, Alzheimer’s disease, and autism.
We have a range of partnership projects that include assisting academic institutions with industrializing their projects to working with biotech companies to harness expertise complementary to our own. In that respect, we are conducting a project with Neurochlore in autism.